Illumina Investor Presentation — January 2021

Document content

39thAnnual Healthcare Conference

President & Chief Executive Officer

January 11, 2021 Cautionary Notes on Forward- Looking Statements

This presentation contains “forward- looking statements ”within the meaning of the federal securities laws, including Section27A of the

Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,as amended. In this context, forward

looking statements often address expected future business and financial performance and financial condition, and often contai n

words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “may,” “target, ”similar expr essions and

variations or negatives of these words. Forward- looking statements by their nature address matters that are, to different degrees,

uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. These and

other forward- looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that

could cause actual results to differ materially from those expressed. Important risk factors that may cause such a difference include,

but are not limited to: (i) the impact to our business and operating results of the COVID -19 pandemic, (ii) changes in the rate of

growth in the markets we serve; (iii) the volume, timing and mix of customer orders among our products and services, (iv) our ability

to adjust our operating expenses to align with our revenue expectations, (v) the outcome of the pending acquisition of GRAIL, Inc.,

(vi) legislative, regulatory and economic developments, (v) the other risks described in the Company’s most recent annual report on

Form 10- K, quarterly reports on Form 10- Q, and in the registration statement on Form S -4 filed with the SEC on November 25, 2020,

and (vii) management’s response to any of the aforementioned factors.

2Pandemic Highlights Sequencing’s Essential Role in Global Health

Identified novel coronavirus

Enabled development of vaccines and

Identification of new strains and

transmission tracking

3Illumina Had a Strong Close to 2020

YoYPreliminary 2020 Results~$950 M

~$1.20 Preliminary Q4 2020 Results

Q1 20 Q2 20 Q3 20 Q4 20E$ Millions

QoQ -10% -26% +26% +20%

YoY 2% -25% -12% Flat~$1.71 GAAP EPSRecord Orders

RevenueRobust 2020 Instrument Placements

RECORD NEXTSEQ SHIPMENTS

Preview truncated — download the full document for the complete content.